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Intrauterine growth restriction (IUGR) implies fetal hypoxia, resulting in blood ﬂow redistribution and sparing of vital organs
(brain, heart). Serum cardiac Troponin-I (cTnI), a well-established marker of myocardial ischaemia, was measured in 40 moth-
ers prior to delivery, the doubly clamped umbilical cords (representing fetal state), and their 20 IUGR and 20 appropriate-for-
gestational-age (AGA) neonates on day 1 and 4 postpartum. At all time points, no diﬀerences in cTnI levels were observed between
the AGA and IUGR groups. Strong positive correlations were documented between maternal and fetal/neonatal values (r ≥ .498,
P ≤ .025 in all cases in the AGA and r ≥ .615, P ≤ .009 in all cases in the IUGR group). These results may indicate (a) normal
heart function, due to heart sparing, in the IUGR group (b) potential crossing of the placental barrier by cTnI in both groups
Copyright © 2007 Nicoletta Iacovidou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cardiac troponin (cTn), an inhibitory protein complex lo-
cated on the actin ﬁlament in all striated muscles, consists of
three subunits T, I, and C [1] and coordinates striated mus-
cle contraction in response to voltage changes [2]. cTnI is
encoded by speciﬁc genes [3], blocks the formation of actin-
myosin bridges [4] and since it is not found in skeletal mus-
cles [5, 6], it is considered a highly speciﬁc indicator of my-
ocardial injury in adults [4]. However, studies have shown
that cTnI is also successfully used in the diagnosis of my-
ocardialinjuryinneonateswithasphyxia,respiratorydistress
syndrome, and septic or cardiogenic shock [7]. Although the
half-life of cTnI is relatively short (90 minutes), its diagnos-
tic time range is unusually wide (ranging from a few hours to
10–14 days after the episode of myocardial injury) as a con-
sequence of intracellular compartmentation [7].
Intrauterine growth restriction (IUGR) caused by the
chronic malnutrition and hypoxia [8, 9] (consequent to
deﬁcient placental transport of nutrients and oxygen [10],
asymmetrical pattern of IUGR) is characterized by blood
ﬂow redistribution to vital organs (brain, myocardium, and
adrenal glands), while other organs are deprived from suﬃ-
cientbloodﬂow.Thisphenomenoncalled“thebrain-sparing
eﬀect” is usually accompanied by oligohydramnios [11, 12].
Taking into account the brain-sparing eﬀect, this study
was based on the hypothesis that circulating cTnI lev-
els should not diﬀer between IUGR and appropriate-for-
gestational age (AGA) full-term infants. Therefore, we aimed
to determine circulating cTnI levels in IUGR and AGA preg-
nancies at time-points characteristic for intra-and extrauter-
ine life, and correlate determined levels with gestational age,
gender, and mode of delivery.
2. SUBJECTS AND METHODS
The Ethics Committee of our teaching hospital approved the
study protocol. All included mothers provided signed in-
formed consent before recruitment. Forty parturients giv-
ing consecutively birth either to 20 AGA or 20 asymmet-
ric IUGR full-term singleton infants with a birth weight be-
low the 3rd customized centile were included in the study.
The Gestation Related Optimal Weight computer-generated
program [13, 14] was used to calculate the customized cen-
tile for each pregnancy, taking into consideration signiﬁ-
cant determinants of birth weight, as maternal height and
booking weight, ethnic group, parity, gestational age, and
gender [13]. Causes of IUGR were identiﬁed in each one
of our 20 IUGR cases. Thus, nine mothers were presented
with preeclampsia and the remaining 11 were presented with
gestational hypertension in addition to other pathological2 Mediators of Inﬂammation
conditions, such as iron-deﬁcient anemia (3 cases), gesta-
tional diabetes mellitus (2 cases), hypothyroidism (3 cases),
extreme obesity (2 cases), and cardiac arrhythmias (1 case).
Five of the above 11 women were smoking more than 10
cigarettes per day during the whole duration of pregnancy.
Doppler studies were performed in the IUGR group ev-
ery 10–15 days, starting from the 32nd gestational week.
During each Doppler velocimetry evaluation, three consec-
utive measurements of the pulsatility index (PI) of the stud-
ied vessel were done and the mean value was recorded. Con-
cerning uterine and umbilical arteries [8, 15], mean PI val-
ues were progressively found to be in the upper physiolog-
ical limits for the corresponding gestational age in 13 cases
(ranging between the 90th and the 95th percentiles), while
in the remaining seven cases, PI values showed increased
impedance to ﬂow, being above the 95th percentile for gesta-
tional age. Regarding middle cerebral arteries [16], Doppler
studies showed resistance to be in the lower physiological
limits for gestational age, indicating the initiation of blood
ﬂow redistribution process. Nevertheless, amniotic ﬂuid was
diminished in all IUGR cases. For the evaluation of the am-
niotic ﬂuid, the largest ﬂuid column on the vertical plane
was assessed and was deﬁned as diminished, if <2cm.Fur-
thermore, placental weight was reduced ranging from 255 to
400g.
In contrast, in the AGA group, mothers were healthy and
were either nonsmokers or had abstained from smoking dur-
ing pregnancy. Moreover, placentas were normal in appear-
ance and weight.
All neonates had no symptoms of intrauterine infec-
tion or stigmata of genetic syndromes. One- and ﬁve-minute
Apgar scores were ≥8 and umbilical cord pH values were
≥7.25inallIUGRcasesandAGAcontrols.Thedemographic
data of participating infants and their mothers are shown in
Table 1.
Blood was collected at speciﬁc time points as follows: (1)
from the mother (MS) during the ﬁrst stage of labour, or be-
fore receiving anaesthesia in cases of elective caesarean sec-
tion, (2) from the doubly clamped umbilical cord (UC), re-
ﬂecting the fetal state, and (3) from the neonates on post-
partum days 1 (N1) and 4 (N4), which are characteristic
for transition and stabilization to extrauterine life, respec-
tively. Blood was collected in pyrogen-free tubes and was im-
mediately centrifuged after clotting. The supernatant serum
was stored at −80◦C until assay. cTnI was determined by a
commercially available enzyme immunoassay kit [troponin
I (human cardiac speciﬁc) enzyme immunoassay test kit,
catalogue number 1105Z, Diagnostic Automation Inc, Cal-
abasas, Calif, USA]. All specimens were run in duplicate.
The detection limit was 0.1ng/mL. The intra- and interas-
saycoeﬃcientsofvariationwere2.8%and6.7%,respectively.
The antibodies used in this assay were highly speciﬁc for
cTnI and there was no cross-reactivity with cTnT or skele-
tal troponin-T.
3. STATISTICAL ANALYSIS
cTnI was normally distributed; thus, Anova for repeated
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Figure 1: Cardiac troponin-I (cTnI) levels in maternal (MS), fe-
tal (UC), neonatal day 1 (N1), and neonatal day 4 (N4) serum
of intrauterine growth-restricted (IUGR) and appropriate-for-
gestational age (AGA) groups. Error bars represent mean and 95%
conﬁdence interval of the mean.
for multiple comparisons, and Spearman’s or Pearson’s cor-
relation coeﬃcient were used as appropriate. P<. 05 was
considered statistically signiﬁcant.
4. RESULTS
Mean (SD) circulating cTnI levels in AGA and IUGR groups
at all time points (MS, UC, N1, and N4) are shown in
Figure 1.Foralltimepoints,nostatisticallysigniﬁcantdiﬀer-
e n c e si nc T n Il e v e l sb e t w e e nI U G Rc a s e sa n dA G Ac o n t r o l s
were documented.
In the AGA group, no statistically signiﬁcant diﬀerences
in cTnI levels were observed between MS, UC, N1, and N4.
MS cTnI levels positively correlated with respective levels in
UC, N1, and N4 (r = .536, P = .018, r = .498, P = .025 and
r = .730, P<. 001, resp.). Additionally, N4 cTnI levels pos-
itively correlated with UC and N1 levels (r = .492, P<. 032
and r = .665, P = .001). As expected, birth weight positively
correlated with gestational age (r = .562, P = .010).
In the IUGR group, MS cTnI levels were signiﬁcantly
l o w e rc o m p a r e dt or e s p e c t i v el e v e l si nN 1( P<. 012) and
N4 (P = .026). Additionally, MS cTnI levels positively cor-
related with respective levels in UC, N1, and N4 (r = .615,
P = .009, r = .847, P<. 001 and r = .770, P<. 001, resp.).
N1 cTnI levels positively correlated with N4 ones (r = .856,
P<. 001). Finally, gestational age positively correlated with
birth weight (r = .555, P = .009).
The eﬀect of gender on cTnI levels was found to be
signiﬁcant in the IUGR group (see Figure 2). Thus, cTnINicoletta Iacovidou et al. 3
Table 1: Demographic data for appropriate-for-gestational age (AGA) and intrauterine growth-restricted (IUGR) neonates and their moth-
ers.
AGA IUGR P value
Mean (SD) Mean (SD)
Birth weight (g) 3356 (223) 2342 (229) <.001
Birth weight customized centile 65.4 (12.6) 1.5 (1.5) <.001
Gestational age (weeks) 38.4 (1) 38.1 (0.7) NS
Gender NS
Male 11 (55%) 11 (55%)
Female 9 (45%) 9 (45%)
Maternal age (years) 28 (4.0) 31 (5.0) NS
Parity NS
First 10 (50%) 11 (55%)
Other 10 (50%) 9 (45%)
Mode of delivery <.013
Vaginal 13 (65%) 8 (40%)
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Figure 2: Cardiac troponin-I (cTnI) levels in maternal (MS), fe-
tal (UC), neonatal day 1 (N1), and neonatal day 4 (N4) serum of
pregnancies with intrauterine growth-restricted (IUGR) male and
female oﬀsprings.
levels were signiﬁcantly lower in mothers with male oﬀ-
spring than female [regression coeﬃcient b: −0.468, 95% CI:
(−0.928/−0.008), P = .047]. Similarly, N1 cTnI levels were
signiﬁcantly lower in males than females [regression coeﬃ-





tic and prognostic marker of myocardial damage and out-
come in paediatric and adult population [17–19], data con-
cerning neonates are relatively limited. In this respect, cTnI
was increased in asphyxiated neonates compared to healthy
ones, suggesting myocardial injury [1]. In addition, cTnI has
beenreportedtobesigniﬁcantlyelevatedinthecordbloodof
critically ill newborns and even higher in nonsurvivors [20],
implying that cTnI could serve as a predictor of mortality
in this group of newborns. Furthermore, increased levels of
cTnI were associated with a lower umbilical artery pH [21],
and have been reported in sick preterm neonates with idio-
pathic respiratory distress [22].
Although some investigators claim that cTnI levels are
undetectable in healthy adults and healthy pregnant women
[23,24],others have given referencerangesfor this substance
[25, 26]. McDonough et al. [27] suggest that under condi-
tionsofmyocardialstress,ischaemiawithoutmyocytenecro-
sis may occur, resulting in intracellular degradation of tro-
ponin and release of its fragments, which are detected in the
serum. The above explanation may justify the presence of
troponin in the maternal circulation in this study.
Ontheotherhand,ithasbeenreportedthathealthyterm
newborns were presented with higher upper reference lim-
its of circulating cTnI than adults [25, 26, 28]. No plausible
explanation why this happens has yet been reached. Never-
theless, this fact may reﬂect programmed cell death, since
apoptosis contributes to the neonatal adaptive changes in
the heart postpartum [29, 30]. Otherwise, this fact could
be attributed to diﬀerent plasmatic eliminations of cTnI in
neonates[31].Inaccordance,ourstudyshowedthatmothers
demonstrated lower cTnI levels than their IUGR infants who
had oligohydramnios and presumably impaired renal func-
tion.4 Mediators of Inﬂammation
Araujo et al. [31] published reference values for cTnI in
healthy term neonates, ranging between 0.01ng/mL (2.5th
centile) and 2.8ng/mL (99th centile). The values of cTnI in
both groups (IUGR and AGA) of the present study range
within these limits; therefore, they suggest no evidence of
myocardial damage (according to criteria for deﬁnition of
myocardial injury [32]) and support our hypothesis that cir-
culating cTnI levels should not diﬀer between IUGR (below
the 3rd customized centile) and AGA full-term infants, due
to sparing of basic organs (e.g., brain, heart). In this respect,
a previous study of ours reported that circulating levels of
neurotrophins, which are important for pre- and postnatal
brain development, did not diﬀer between IUGR and AGA
groups [33].
According to our results, cTnI seems to cross the placen-
t a lb a r r i e r ,s i n c ep o s i t i v ec o r r e l a t i o n sb e t w e e nm a t e r n a la n d
fetal/neonatal cTnI levels were documented for both IUGR
and AGA groups. No relevant reports for cTnI exist in the
literature; however, for cTnT experimental evidence suggests
nontransplacental passage [34].
Our ﬁnding that maternal and neonatal cTnI levels are
lower when the IUGR oﬀspring is a male has not been pre-
viously reported. Relatively, Baum et al. [28]h a v ed e m o n -
strated that male newborns have a signiﬁcantly higher me-
dian cTnT value than females, while no respective diﬀer-
ence was observed in their study concerning cTnI levels. On
the contrary, other investigators give similar cTnT values for
males and females [35].
In conclusion, circulating cTnI levels do not diﬀer be-
tween IUGR cases and AGA controls, possibly due to the
sparingofvitalorgans,liketheheart.Furthermore,cTnIpos-
sibly crosses the placenta, as strong correlations between ma-
ternal and fetal/neonatal values are documented. Lastly, ma-
ternal and neonatal cTnI levels are lower when the IUGR oﬀ-
spring is of male gender.
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